Eisai Co., Ltd. has announced promising findings for its investigational anti-MTBR antibody, etalanetug, which demonstrated a reduction in plasma eMTBR-tau243, a key biomarker associated with Alzheimer's disease (AD) tau tangle pathology. The results were shared at the Alzheimer’s Association International Conference 2026. Etalanetug targets the microtubule-binding region of tau protein, potentially preventing the progression of tau pathology in the brain. […]